ClinicalTrials.gg
CompletedNCT00515697Updated Jun 18, 2014Results posted

A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma

A Phase 2 interventional study of Ramucirumab in Metastatic Renal Cell Carcinoma, sponsored by Eli Lilly and Company. Completed at 11 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-06-18.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
39
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 10 studies in Carcinoma, Renal Cell by Eli Lilly and Company — none open to participants now, none under way, none of them phase 3. Carcinoma, Renal Cell · Eli Lilly and Company.

Started
2007
the only one that year
Phase 2
3 of 10
none open now
Registered
1st of 10
by date

Among the 10 studies in Carcinoma, Renal Cell by Eli Lilly and Company, this one is the only one that started in 2007, is one of 3 in phase 2, and was the 1st registered.

Carcinoma, Renal Cell

2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

None of the 10 studies in Carcinoma, Renal Cell by Eli Lilly and Company is open now. The open studies under Carcinoma, Renal Cell, anywhere →

Who these studies take

Of the 307 Carcinoma, Renal Cell studies recruiting now, 254 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 20 take children under 18; 19 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Carcinoma, Renal Cell by Eli Lilly and Company as a file.
02

Study summary

The purpose of this study is to determine whether ramucirumab is effective treatment in participants with metastatic renal cell carcinoma who have developed progressive disease or become intolerant to tyrosine kinase inhibitor therapy.

Read the detailed description

The Primary objective is to determine the best objective response rate (ORR) of ramucirumab when administered to participants with metastatic renal cell carcinoma (RCC) whose disease has progressed during therapy with a tyrosine kinase inhibitor (TKI, sunitinib and/or sorafenib) or who have developed intolerance to these agents.

03

Conditions studied

  • Metastatic Renal Cell Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant has or cytologically confirmed clear cell RCC
  • The participant is ≥ 18 years of age
  • The participant has an performance status (ECOG PS) of 0-1 or Performance Status (KPS) ≥ 80%
  • The participant has had a prior nephrectomy (as therapy for RCC)
  • The participant has RCC
  • The participant has a of > 3 months
  • The participant has as defined by (RECIST)
  • The participant has received prior therapy with a TKI (sunitinib and/or sorafenib) with either disease progression on TKI therapy (progression within 60 days of the last dose of TKI) or intolerance to TKI (unable to continue therapy because of side-effects). A participant with progression during a protracted treatment break is not eligible unless the participant has had progression or intolerance as defined above
  • The participant has resolution of all toxic effects of prior cancer therapy to grade ≤ 1 by the National Cancer Institute , version 3.0 (NCI-CTCAE)
  • The participant has adequate hematological functions [ (ANC) ≥ 1500 cells per milliliter (cells/mL), ≥ 9 grams per deciliter (g/dL) and ≥ 100,000 cells/mL]
  • The participant has adequate hepatic function [ within normal limits (WNL), (AST) and/or alanine transaminase (ALT) ≤ 2.5 times the (ULN), or ≤ 5.0 times the ULN if the transaminase elevation is due to liver metastases]
  • The participant has normal renal function or mild renal dysfunction [creatinine ≤ 2.2 milligrams per deciliter (mg/dL)]
  • The participant's urinary protein ≤ 1+ on dipstick or routine urinalysis [(UA); if urine dipstick or routine analysis is ≥ 2+, a 24-hour urine for protein must demonstrate \< 1000 (milligrams) mg of protein in 24 hours to allow participation in the study]
  • The participant must have adequate coagulation function as defined by (INR) ≤ 1.8 and a partial thromboplastin time (PTT) ≤ 1.5 X ULN. Participants on full-dose anticoagulation must be on a stable dose of oral anticoagulant or low molecular weight (LMW) heparin and if on warfarin must have a INR between 2 and 3 and have no active bleeding or pathological condition that carries a high risk of bleeding (for example, tumor involving major vessels or known varices)
  • The participant is able to provide informed written consent
  • The participant , if sexually active, is (last menstrual period > 2 years prior to study), surgically sterile, or is using effective method of in the opinion of the investigator
  • The participant , if female, must have a negative serum pregnancy test upon entry into this study
  • The participant has a normal thyroid stimulating hormone (TSH) value. Participants with an abnormal TSH may be eligible provided they meet all other eligibility criteria and have ECOG performance status 0-1. Participants with an abnormal TSH value require a full thyroid evaluation prior to enrollment. Endocrinology consultation may be performed at the discretion of the investigator
  • The participant has serum calcium within normal limits

Exclusion criteria

Exclusion Criteria:

  • The participant has received prior treatment with bevacizumab
  • The participant has known brain or
  • The participant has received >2 prior cytotoxic chemotherapy regimens for RCC
  • The participant has received antitumor therapy (biologic agents, major surgery, or agent) within 28 days prior to enrollment on study. The participant has received radiation therapy within 14 days prior to enrollment on study. Participants with in weight bearing bones at high risk for pathologic fracture may participate provided that appropriate surgical intervention and/or radiation therapy is undertaken and completed at least 28 days prior to enrollment
  • The participant has received > 1 prior bio-immunotherapy regimens (defined as either interleukin-2 or interferon alpha given as monotherapy, concurrently, or sequentially as planned)
  • The participant has a concurrent active other than adequately treated non-melanomatous skin cancer or other non-invasive carcinoma or in situ neoplasm. A participant with previous history of malignancy is eligible, provided that he/she has been disease free for > 3 years
  • The participant has a nonhealing wound or ulcer
  • The participant has a known alcohol or drug dependency
  • The participant is pregnant or breastfeeding
  • The participant has a coexisting medical or psychiatric problem of sufficient severity to limit compliance with the study and/or increase the risks associated with study participation or study drug administration or interfere with the interpretation of study results
  • The participant has an ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, symptomatic or poorly controlled cardiac arrhythmia, psychiatric illness/social situations, or any other serious uncontrolled medical disorders in the opinion of the investigator
  • The participant has known infection or acquired immunodeficiency syndrome-related illness
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    Ramucirumab

    Intravenous infusion at 8 milligrams per kilogram (mg/kg) on day 1 of every 14-day cycle.

    Biological: Ramucirumab

Interventions

  • BiologicalRamucirumab

    Ramucirumab is an injectable solution administered as an intravenous infusion over 1 hour at a dose of 8 mg/kg day 1 of every 14-day cycle.

    Also known as: IMC-1121B, LY3009806

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Objective Response (Objective Response Rate)

    The percentage of participants with a best overall response of confirmed complete response (CR) or partial response (PR) as classified according to Response Evaluation Criteria In Solid Tumors (RECIST, version 1.0) criteria. CR is the disappearance of all target and non-target lesions and normalization of tumor marker levels. PR is having at least a 30% decrease in the sum of the longest diameter of target lesions without new lesions and progression of non-target lesions. The percentage of participants with objective response=(number of participants whose best overall response during therapy is CR or PR/number of participants treated)\*100.

    Time frame: First dose to date of objective progressive disease or death due to any cause (up to 34 months)

Secondary outcomes

  1. Progression-Free Survival

    Progression-free survival (PFS) is measured from the date of the first dose to the first documented date of disease progression as classified according to Response Evaluation Criteria In Solid Tumors (RECIST, version 1.0) criteria or death from any cause. Disease progression is having at least a 20% increase in the sum of the longest diameter of target lesions and/or unequivocal progression of a non-target lesion and/or detection of a new lesion. Data for participants whose disease does not progress or for whom no post-baseline assessment is made are censored at the day of their last tumor assessment. Data for participants whose disease does not progress who are subsequently lost to follow-up are also censored at the day of their last tumor assessment.

    Time frame: First dose to measured progressive disease or death due to any cause (up to 34 months)

  2. Percentage of Participants Showing Disease Control at Week 12

    Participants who were alive and did not experience disease progression were considered to have disease control at 12 weeks. Disease control was based on lack of disease progression using Response Evaluation Criteria In Solid Tumors (RECIST, version 1.0) criteria. According to RECIST criteria, disease progression was having at least a 20% increase in the sum of the longest diameter of target lesions and/or unequivocal progression of non-target lesion and/or detection of new lesion. Participants whose disease progression was symptomatic were not considered to have disease control. The percentage of participants showing disease control=(number of participants who did not have disease or symptomatic progression at Week 12/number of participants treated)\*100.

    Time frame: Week 12 [Cycle 6 (1 cycle=14 days)]

  3. Percentage of Participants With Objective Response (Objective Response Rate) at 12 Weeks

    The percentage of participants with a confirmed best overall response of complete response (CR) or partial response (PR) at Week 12, as classified according to Response Evaluation Criteria In Solid Tumors (RECIST, version 1.0) criteria. CR is the disappearance of all target and non-target lesions and the normalization of tumor marker levels. PR is having at least a 30% decrease in the sum of the longest diameter of target lesions without new lesions and progression of non-target lesions. The percentage of participants with objective response=(number of participants whose best overall response achieved at 12 weeks was CR or PR/number of participants treated)\*100.

    Time frame: Week 12 [Cycle 6 (1 cycle=14 days)]

  4. Median Duration of Overall Response

    Duration of response is the interval from the date of initial documented response \[confirmed complete response (CR) or partial response (PR)\] to the first documented date of disease progression as classified according to Response Evaluation Criteria In Solid Tumors (RECIST version 1.0) criteria, or initiation of other (or additional) antitumor therapy is first reported, or death due to any cause. CR is the disappearance of all target and non-target lesions and the normalization of tumor marker levels. PR is having at least a 30% decrease in the sum of the longest diameter of target lesions without new lesions and progression of non-target lesions. Disease progression is having at least a 20% increase in the sum of the longest diameter of target lesions and/or unequivocal progression of a non-target lesion and/or detection of a new lesion. Data from participants who did not relapse were censored on the day of their last tumor assessment.

    Time frame: Time of first response (CR or PR) to disease progression, initiation of other (or additional) antitumor therapy, or death due to any cause (up to 34 months)

  5. Minimum Concentration (Cmin) of Ramucirumab

    Time frame: Immediately prior to the Week 32 infusion treatment [Cycle 16 (1 cycle=14 days)]

  6. Maximum Concentration (Cmax) of Ramucirumab

    Time frame: 1 hour after the end of the Week 32 infusion treatment [Cycle 16 (1 cycle=14 days)]

  7. Summary Listing of Participants Reporting Drug-Related Treatment-Emergent Adverse Events

    Data presented are the number of participants who experienced treatment-emergent adverse events (TEAE), serious adverse events (SAE), Grade 3 or 4 TEAE, or adverse events (AE) leading to discontinuation of treatment that were considered to be related to ramucirumab. A summary of SAEs and other nonserious AEs, regardless of causality, is located in the Reported Adverse Events section.

    Time frame: First dose to study completion (up to 34 months) plus 30-day safety follow-up

07

Results

Posted Jun 18, 2014

Participant flow

Participant flow — Overall Study
MilestoneRamucirumab
Started39
Received at least 1 dose of study drug39
Completed39
Not completed0

Outcome measures

PrimaryPercentage of Participants With Objective Response (Objective Response Rate)

The percentage of participants with a best overall response of confirmed complete response (CR) or partial response (PR) as classified according to Response Evaluation Criteria In Solid Tumors (RECIST, version 1.0) criteria. CR is the disappearance of all target and non-target lesions and normalization of tumor marker levels. PR is having at least a 30% decrease in the sum of the longest diameter of target lesions without new lesions and progression of non-target lesions. The percentage of participants with objective response=(number of participants whose best overall response during therapy is CR or PR/number of participants treated)\*100.

Time frame:
First dose to date of objective progressive disease or death due to any cause (up to 34 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Response (Objective Response Rate)
percentage of participantsRamucirumab
Percentage of Participants With Objective Response (Objective Response Rate)5.1 (0.6 to 17.3)
SecondaryProgression-Free Survival

Progression-free survival (PFS) is measured from the date of the first dose to the first documented date of disease progression as classified according to Response Evaluation Criteria In Solid Tumors (RECIST, version 1.0) criteria or death from any cause. Disease progression is having at least a 20% increase in the sum of the longest diameter of target lesions and/or unequivocal progression of a non-target lesion and/or detection of a new lesion. Data for participants whose disease does not progress or for whom no post-baseline assessment is made are censored at the day of their last tumor assessment. Data for participants whose disease does not progress who are subsequently lost to follow-up are also censored at the day of their last tumor assessment.

Time frame:
First dose to measured progressive disease or death due to any cause (up to 34 months)
Reported as:
Median · months
Progression-Free Survival
monthsRamucirumab
Progression-Free Survival7.1 (4.1 to 9.7)
SecondaryPercentage of Participants Showing Disease Control at Week 12

Participants who were alive and did not experience disease progression were considered to have disease control at 12 weeks. Disease control was based on lack of disease progression using Response Evaluation Criteria In Solid Tumors (RECIST, version 1.0) criteria. According to RECIST criteria, disease progression was having at least a 20% increase in the sum of the longest diameter of target lesions and/or unequivocal progression of non-target lesion and/or detection of new lesion. Participants whose disease progression was symptomatic were not considered to have disease control. The percentage of participants showing disease control=(number of participants who did not have disease or symptomatic progression at Week 12/number of participants treated)\*100.

Time frame:
Week 12 [Cycle 6 (1 cycle=14 days)]
Reported as:
Number · percentage of participants
Percentage of Participants Showing Disease Control at Week 12
percentage of participantsRamucirumab
Percentage of Participants Showing Disease Control at Week 1264.1 (47.2 to 78.8)
SecondaryPercentage of Participants With Objective Response (Objective Response Rate) at 12 Weeks

The percentage of participants with a confirmed best overall response of complete response (CR) or partial response (PR) at Week 12, as classified according to Response Evaluation Criteria In Solid Tumors (RECIST, version 1.0) criteria. CR is the disappearance of all target and non-target lesions and the normalization of tumor marker levels. PR is having at least a 30% decrease in the sum of the longest diameter of target lesions without new lesions and progression of non-target lesions. The percentage of participants with objective response=(number of participants whose best overall response achieved at 12 weeks was CR or PR/number of participants treated)\*100.

Time frame:
Week 12 [Cycle 6 (1 cycle=14 days)]
Reported as:
Number · percentage of participants
Percentage of Participants With Objective Response (Objective Response Rate) at 12 Weeks
percentage of participantsRamucirumab
Percentage of Participants With Objective Response (Objective Response Rate) at 12 Weeks0.0 (0.0 to 9.0)
SecondaryMedian Duration of Overall Response

Duration of response is the interval from the date of initial documented response \[confirmed complete response (CR) or partial response (PR)\] to the first documented date of disease progression as classified according to Response Evaluation Criteria In Solid Tumors (RECIST version 1.0) criteria, or initiation of other (or additional) antitumor therapy is first reported, or death due to any cause. CR is the disappearance of all target and non-target lesions and the normalization of tumor marker levels. PR is having at least a 30% decrease in the sum of the longest diameter of target lesions without new lesions and progression of non-target lesions. Disease progression is having at least a 20% increase in the sum of the longest diameter of target lesions and/or unequivocal progression of a non-target lesion and/or detection of a new lesion. Data from participants who did not relapse were censored on the day of their last tumor assessment.

Time frame:
Time of first response (CR or PR) to disease progression, initiation of other (or additional) antitumor therapy, or death due to any cause (up to 34 months)
Reported as:
Median · months
Median Duration of Overall Response
monthsRamucirumab
Median Duration of Overall ResponseNA (2.8 to NA)
SecondaryMinimum Concentration (Cmin) of Ramucirumab
Time frame:
Immediately prior to the Week 32 infusion treatment [Cycle 16 (1 cycle=14 days)]
Reported as:
Mean · micrograms per milliliter (mcg/mL)
Minimum Concentration (Cmin) of Ramucirumab
micrograms per milliliter (mcg/mL)Ramucirumab
Minimum Concentration (Cmin) of Ramucirumab147 ± 76.2
SecondaryMaximum Concentration (Cmax) of Ramucirumab
Time frame:
1 hour after the end of the Week 32 infusion treatment [Cycle 16 (1 cycle=14 days)]
Reported as:
Mean · micrograms per milliliter (mcg/mL)
Maximum Concentration (Cmax) of Ramucirumab
micrograms per milliliter (mcg/mL)Ramucirumab
Maximum Concentration (Cmax) of Ramucirumab595 ± 239
SecondarySummary Listing of Participants Reporting Drug-Related Treatment-Emergent Adverse Events

Data presented are the number of participants who experienced treatment-emergent adverse events (TEAE), serious adverse events (SAE), Grade 3 or 4 TEAE, or adverse events (AE) leading to discontinuation of treatment that were considered to be related to ramucirumab. A summary of SAEs and other nonserious AEs, regardless of causality, is located in the Reported Adverse Events section.

Time frame:
First dose to study completion (up to 34 months) plus 30-day safety follow-up
Reported as:
Number · participants
Summary Listing of Participants Reporting Drug-Related Treatment-Emergent Adverse Events
participantsRamucirumab
Related TEAE37
Related SAE6
Related Grade 3 or 4 TEAE10
Related AE leading to discontinuation7

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ramucirumab—12/39 (30.8%)39/39 (100%)
Most frequent serious events
Showing 10 of 17
Most frequent serious events
EventRamucirumab
CARDIO-RESPIRATORY ARRESTCardiac disorders1/39
MYOCARDIAL INFARCTIONCardiac disorders1/39
FATIGUEGeneral disorders1/39
MULTI-ORGAN FAILUREGeneral disorders1/39
URINARY TRACT INFECTIONInfections and infestations1/39
ANOREXIAMetabolism and nutrition disorders1/39
BACK PAINMusculoskeletal and connective tissue disorders1/39
ALTERED STATE OF CONSCIOUSNESSNervous system disorders1/39
CEREBRAL ISCHAEMIANervous system disorders1/39
NEUROPATHY PERIPHERALNervous system disorders1/39
Most frequent other events
Showing 10 of 67
Most frequent other events
EventRamucirumab
FATIGUEGeneral disorders19/39
OEDEMA PERIPHERALGeneral disorders14/39
HEADACHENervous system disorders14/39
EPISTAXISRespiratory, thoracic and mediastinal disorders13/39
ARTHRALGIAMusculoskeletal and connective tissue disorders12/39
NAUSEAGastrointestinal disorders10/39
ANOREXIAMetabolism and nutrition disorders10/39
VOMITINGGastrointestinal disorders9/39
CONSTIPATIONGastrointestinal disorders8/39
BACK PAINMusculoskeletal and connective tissue disorders8/39

Baseline characteristics

Intent-to-treat population: participants who received any quantity of ramucirumab.

Age, Customized
Age, Customized(participants)Ramucirumab
Between 18 and 65 years27
>=65 years12
Sex: Female, Male
Sex: Female, Male(Participants)Ramucirumab
Female8
Male31
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Ramucirumab
White35
Black or African American3
Asian1
American Indian or Alaska Native0
Native Hawaiian or Other Pacific Islander0
More than one race0
Region of Enrollment
Region of Enrollment(participants)Ramucirumab
United States39
Ethnicity
Ethnicity(participants)Ramucirumab
Hispanic or Latino1
Not Hispanic or Latino38
08

Study locations

11 sites
  • ImClone Investigational Site
    San Francisco, California 94115, United States
  • ImClone Investigational Site
    Chicago, Illinois 60637, United States
  • ImClone Investigational Site
    Metairie, Louisiana 70006, United States
  • ImClone Investigational Site
    Boston, Massachusetts 02115, United States
  • ImClone Investigational Site
    Flemington, New Jersey 08822, United States
  • ImClone Investigational Site
    Buffalo, New York 14263, United States
  • ImClone Investigational Site
    Cleveland, Ohio 44195, United States
  • ImClone Investigational Site
    Drexel Hill, Pennsylvania 19026, United States
  • ImClone Investigational Site
    Philadelphia, Pennsylvania 19111, United States
  • ImClone Investigational Site
    Arlington, Texas 76012, United States
  • ImClone Investigational Site
    Seattle, Washington 98109, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2007, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2014, 3 years 1 month after primary completion. A results delay was requested in Jul 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2007
First posted
Aug 14, 2007
Start
Nov 2007
Primary completionActual
May 2011
CompletionActual
May 2011
Results delay requested
Jul 29, 2010
Results first posted
Jun 18, 2014
Last update
Jun 18, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00515697
Responsible party
Sponsor
First posted
Aug 14, 2007
Start date
Nov 2007
Primary completion
May 2011
Completion
May 2011
Results posted
Jun 18, 2014
Last update
Jun 18, 2014

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ramucirumab

Start the discussion